Home › Research › Biomarkers
Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease
Arranz J, Zhu N, Rubio-Guerra S, Rodríguez-Baz Í, Ferrer R, Carmona-Iragui M, Barroeta I, Illán-Gala I et al.. Alzheimer's research & therapy, 2024-06-26
Topic: Amyloid, tau and blood-test diagnosis
Background Recently developed blood markers for Alzheimer's disease (AD) detection have high accuracy but usually require ultra-sensitive analytic tools not commonly available in clinical laboratories, and their performance in clinical practice is unknown. Methods We analyzed plasma samples from 290 consecutive participants that underwent lumbar puncture in routine clinical practice in a specialized memory clinic (66 cognitively unimpaired, 130 participants with mild cognitive impairment, and 94 with dementia). Participants were classified as amyloid positive (A +) or negative (A-) according to CSF Aβ 1-42 /Aβ 1-40 ratio. Plasma pTau 217 , pTau 181 , Aβ 1-42 and Aβ 1-40 were measured in the fully-automated LUMIPULSE platform. We used linear regression to compare plasma biomarkers concentrations between A + and A- groups, evaluated Spearman's correlation between plasma and CSF and performed ROC analyses to assess their diagnostic accuracy to detect brain amyloidosis as determined by CSF Aβ 1-42 /Aβ 1-40 ratio. We analyzed the concordance of pTau 217 with CSF amyloidosis. Results Plasma pTau 217 and pTau 181 concentration were higher in A + than A- while the plasma Aβ 1-42 /Aβ 1-40 ratio was lower in A + compared to A-. pTau 181 and the Aβ 1-42 /Aβ 1-40 ratio showed moderate correlation between plasma and CSF (Rho = 0.66 and 0.69, respectively). The areas under the ROC curve to discriminate A + from A- participants were 0.94 (95% CI 0.92-0.97) for pTau 217 , and 0.88 (95% CI 0.84-0.92) for both pTau 181 and Aβ 1-42 /Aβ 1-40 . Chronic kidney disease (CKD) was related to increased plasma biomarker concentrations, but ratios were less affected. Plasma pTau 217 had the highest fold change (× 3.2) and showed high predictive capability in discriminating A + from A-, having 4-7% misclassification rate. The global accuracy of plasma pTau 217 using a two-threshold approach was robust in symptomatic groups, exceeding 90%. Conclusion The evaluation of blood biomarkers on an automated platform exhibited high diagnostic accuracy for AD pathophysiology, and pTau 217 showed excellent diagnostic accuracy to identify participants with AD in a consecutive sample representing the routine clinical practice in a specialized memory unit.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Arranz, J., Zhu, N., Rubio-Guerra, S., Í, R.-B., Ferrer, R., Carmona-Iragui, M., et al. (2024). Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-024-01513-9
Vancouver
Arranz J, Zhu N, Rubio-Guerra S, Í R.-B, Ferrer R, Carmona-Iragui M, et al. Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease. Alzheimer's research & therapy. 2024. doi:10.1186/s13195-024-01513-9. PMID: 38926773.
BibTeX
@article{arranz2024-38926773,
author = {Arranz, J. and Zhu, N. and Rubio-Guerra, S. and Í, Rodríguez-Baz and Ferrer, R. and Carmona-Iragui, M. and Barroeta, I. and Illán-Gala, I. and others},
title = {{Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease}},
journal = {Alzheimer's research \& therapy},
year = {2024},
doi = {10.1186/s13195-024-01513-9},
pmid = {38926773},
url = {https://doi.org/10.1186/s13195-024-01513-9}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Plasma pTau 217 and pTau 181 concentration were higher in A + than A- while the plasma Aβ 1-42 /Aβ 1-40 ratio was lower in A + compared to A-. pTau 181 and the Aβ 1-42 /Aβ 1-40 ratio showed moderate correlation between plasma and CSF (Rho = 0.66 and 0.69, respectively).
Why it matters
In plasma samples from people in a memory clinic, pTau217 and pTau181 were higher and the Aβ42/40 ratio lower in those with amyloid positivity on CSF testing. This concerns a blood test for detecting brain amyloidosis, not treating, curing or preventing Alzheimer disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants130
- Evidence strengthLow
How this study scored 58/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | 1 / 4 | Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 130 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 140 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 35.0 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 5 / 6 | Cited 38.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 22 other studies in this library |
| Still being cited | 3 / 4 | Cited 140 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Daniel Andres Alcolea: h-index 66 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Universitat Autònoma de Barcelona: institution h-index 782 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38926773) |
| Free to read | 2 / 2 | Free to read |
| Total | 58 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.
Later studies that cite this one
22 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Biomarkers
Also tagged “cerebrospinal”
822 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 822 tagged studies.